ID   P5CR1_HUMAN             Reviewed;         319 AA.
AC   P32322; A6NFM2; B4DMU0; Q6FHI4; Q96DI6; Q9HBQ4;
DT   01-OCT-1993, integrated into UniProtKB/Swiss-Prot.
DT   01-MAR-2005, sequence version 2.
DT   07-APR-2021, entry version 197.
DE   RecName: Full=Pyrroline-5-carboxylate reductase 1, mitochondrial;
DE            Short=P5C reductase 1;
DE            Short=P5CR 1;
DE            EC=1.5.1.2 {ECO:0000269|PubMed:16730026};
GN   Name=PYCR1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=1730675;
RA   Dougherty K.M., Brandriss M.C., Valle D.;
RT   "Cloning human pyrroline-5-carboxylate reductase cDNA by complementation in
RT   Saccharomyces cerevisiae.";
RL   J. Biol. Chem. 267:871-875(1992).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RA   Gu J.R., Wan D.F., Zhao X.T., Zhou X.M., Jiang H.Q., Zhang P.P., Qin W.X.,
RA   Huang Y., Qiu X.K., Qian L.F., He L.P., Li H.N., Yu Y., Yu J., Han L.H.;
RT   "Novel Human cDNA clones with function of inhibiting cancer cell growth.";
RL   Submitted (DEC-1999) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3).
RC   TISSUE=Brain;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RA   Halleck A., Ebert L., Mkoundinya M., Schick M., Eisenstein S., Neubert P.,
RA   Kstrang K., Schatten R., Shen B., Henze S., Mar W., Korn B., Zuo D., Hu Y.,
RA   LaBaer J.;
RT   "Cloning of human full open reading frames in Gateway(TM) system entry
RT   vector (pDONR201).";
RL   Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16625196; DOI=10.1038/nature04689;
RA   Zody M.C., Garber M., Adams D.J., Sharpe T., Harrow J., Lupski J.R.,
RA   Nicholson C., Searle S.M., Wilming L., Young S.K., Abouelleil A.,
RA   Allen N.R., Bi W., Bloom T., Borowsky M.L., Bugalter B.E., Butler J.,
RA   Chang J.L., Chen C.-K., Cook A., Corum B., Cuomo C.A., de Jong P.J.,
RA   DeCaprio D., Dewar K., FitzGerald M., Gilbert J., Gibson R., Gnerre S.,
RA   Goldstein S., Grafham D.V., Grocock R., Hafez N., Hagopian D.S., Hart E.,
RA   Norman C.H., Humphray S., Jaffe D.B., Jones M., Kamal M., Khodiyar V.K.,
RA   LaButti K., Laird G., Lehoczky J., Liu X., Lokyitsang T., Loveland J.,
RA   Lui A., Macdonald P., Major J.E., Matthews L., Mauceli E., McCarroll S.A.,
RA   Mihalev A.H., Mudge J., Nguyen C., Nicol R., O'Leary S.B., Osoegawa K.,
RA   Schwartz D.C., Shaw-Smith C., Stankiewicz P., Steward C., Swarbreck D.,
RA   Venkataraman V., Whittaker C.A., Yang X., Zimmer A.R., Bradley A.,
RA   Hubbard T., Birren B.W., Rogers J., Lander E.S., Nusbaum C.;
RT   "DNA sequence of human chromosome 17 and analysis of rearrangement in the
RT   human lineage.";
RL   Nature 440:1045-1049(2006).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Lymph, and Placenta;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   PROTEIN SEQUENCE OF 2-17 AND 205-215, CLEAVAGE OF INITIATOR METHIONINE,
RP   ACETYLATION AT SER-2, AND IDENTIFICATION BY MASS SPECTROMETRY.
RC   TISSUE=Colon carcinoma;
RA   Bienvenut W.V., Zebisch A., Kolch W.;
RL   Submitted (DEC-2008) to UniProtKB.
RN   [9]
RP   PROTEIN SEQUENCE OF 2-46; 130-147; 205-215 AND 252-264, CLEAVAGE OF
RP   INITIATOR METHIONINE, ACETYLATION AT SER-2, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY.
RC   TISSUE=Embryonic kidney;
RA   Bienvenut W.V., Waridel P., Quadroni M.;
RL   Submitted (MAR-2009) to UniProtKB.
RN   [10]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT SER-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in a
RT   refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [11]
RP   FUNCTION, SUBCELLULAR LOCATION, VARIANTS ARCL2B GLY-119; HIS-119; THR-179;
RP   TRP-206 AND ARG-206, VARIANTS ARCL3B HIS-251 AND THR-257, AND VARIANT
RP   VAL-189.
RX   PubMed=19648921; DOI=10.1038/ng.413;
RA   Reversade B., Escande-Beillard N., Dimopoulou A., Fischer B., Chng S.C.,
RA   Li Y., Shboul M., Tham P.-Y., Kayserili H., Al-Gazali L., Shahwan M.,
RA   Brancati F., Lee H., O'Connor B.D., Schmidt-von Kegler M., Merriman B.,
RA   Nelson S.F., Masri A., Alkazaleh F., Guerra D., Ferrari P., Nanda A.,
RA   Rajab A., Markie D., Gray M., Nelson J., Grix A., Sommer A.,
RA   Savarirayan R., Janecke A.R., Steichen E., Sillence D., Hausser I.,
RA   Budde B., Nuernberg G., Nuernberg P., Seemann P., Kunkel D., Zambruno G.,
RA   Dallapiccola B., Schuelke M., Robertson S., Hamamy H., Wollnik B.,
RA   Van Maldergem L., Mundlos S., Kornak U.;
RT   "Mutations in PYCR1 cause cutis laxa with progeroid features.";
RL   Nat. Genet. 41:1016-1021(2009).
RN   [12]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [13]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [14]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-278 AND SER-301, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [15]
RP   INTERACTION WITH LTO1.
RX   PubMed=24930674; DOI=10.18632/oncotarget.1561;
RA   Togashi Y., Arao T., Kato H., Matsumoto K., Terashima M., Hayashi H.,
RA   de Velasco M.A., Fujita Y., Kimura H., Yasuda T., Shiozaki H., Nishio K.;
RT   "Frequent amplification of ORAOV1 gene in esophageal squamous cell cancer
RT   promotes an aggressive phenotype via proline metabolism and ROS
RT   production.";
RL   Oncotarget 5:2962-2973(2014).
RN   [16]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M., Ayoub D.,
RA   Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [17]
RP   X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) OF APOENZYME AND IN COMPLEXES WITH
RP   NAD; NADP AND SUBSTRATE ANALOG GLU, CATALYTIC ACTIVITY, FUNCTION, ACTIVITY
RP   REGULATION, BIOPHYSICOCHEMICAL PROPERTIES, MUTAGENESIS OF GLU-221, AND
RP   SUBUNIT.
RX   PubMed=16730026; DOI=10.1016/j.jmb.2006.04.053;
RA   Meng Z., Lou Z., Liu Z., Li M., Zhao X., Bartlam M., Rao Z.;
RT   "Crystal structure of human pyrroline-5-carboxylate reductase.";
RL   J. Mol. Biol. 359:1364-1377(2006).
RN   [18]
RP   X-RAY CRYSTALLOGRAPHY (1.95 ANGSTROMS) OF 1-300 IN COMPLEX WITH NAD.
RG   Structural genomics consortium (SGC);
RT   "Crystal structure of human pyrroline-5-carboxylate reductase.";
RL   Submitted (FEB-2009) to the PDB data bank.
RN   [19]
RP   VARIANT ARCL2B GLN-266.
RX   PubMed=19576563; DOI=10.1016/j.ajhg.2009.06.008;
RA   Guernsey D.L., Jiang H., Evans S.C., Ferguson M., Matsuoka M.,
RA   Nightingale M., Rideout A.L., Provost S., Bedard K., Orr A., Dube M.-P.,
RA   Ludman M., Samuels M.E.;
RT   "Mutation in pyrroline-5-carboxylate reductase 1 gene in families with
RT   cutis laxa type 2.";
RL   Am. J. Hum. Genet. 85:120-129(2009).
RN   [20]
RP   VARIANT ARCL3B GLU-248, AND VARIANT ARG-297.
RX   PubMed=22052856; DOI=10.1002/ajmg.a.34326;
RA   Lin D.S., Chang J.H., Liu H.L., Wei C.H., Yeung C.Y., Ho C.S., Shu C.H.,
RA   Chiang M.F., Chuang C.K., Huang Y.W., Wu T.Y., Jian Y.R., Huang Z.D.,
RA   Lin S.P.;
RT   "Compound heterozygous mutations in PYCR1 further expand the phenotypic
RT   spectrum of De Barsy syndrome.";
RL   Am. J. Med. Genet. A 155:3095-3099(2011).
CC   -!- FUNCTION: Housekeeping enzyme that catalyzes the last step in proline
CC       biosynthesis. Can utilize both NAD and NADP, but has higher affinity
CC       for NAD. Involved in the cellular response to oxidative stress.
CC       {ECO:0000269|PubMed:16730026, ECO:0000269|PubMed:19648921}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=L-proline + NADP(+) = 1-pyrroline-5-carboxylate + 2 H(+) +
CC         NADPH; Xref=Rhea:RHEA:14109, ChEBI:CHEBI:15378, ChEBI:CHEBI:15893,
CC         ChEBI:CHEBI:57783, ChEBI:CHEBI:58349, ChEBI:CHEBI:60039; EC=1.5.1.2;
CC         Evidence={ECO:0000269|PubMed:16730026};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=L-proline + NAD(+) = 1-pyrroline-5-carboxylate + 2 H(+) +
CC         NADH; Xref=Rhea:RHEA:14105, ChEBI:CHEBI:15378, ChEBI:CHEBI:15893,
CC         ChEBI:CHEBI:57540, ChEBI:CHEBI:57945, ChEBI:CHEBI:60039; EC=1.5.1.2;
CC         Evidence={ECO:0000269|PubMed:16730026};
CC   -!- ACTIVITY REGULATION: Subject to competitive inhibition by the reaction
CC       product proline. Subject to competitive inhibition by stearoyl coenzyme
CC       A. {ECO:0000269|PubMed:16730026}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=0.151 mM for NAD(+) {ECO:0000269|PubMed:16730026};
CC         KM=3.06 mM for NADP(+) {ECO:0000269|PubMed:16730026};
CC   -!- PATHWAY: Amino-acid biosynthesis; L-proline biosynthesis; L-proline
CC       from L-glutamate 5-semialdehyde: step 1/1.
CC   -!- SUBUNIT: Homodecamer; composed of 5 homodimers (PubMed:16730026,
CC       Ref.18). Interacts with LTO1 (PubMed:24930674).
CC       {ECO:0000269|PubMed:16730026, ECO:0000269|PubMed:24930674,
CC       ECO:0000269|Ref.18}.
CC   -!- INTERACTION:
CC       P32322; Q99497: PARK7; NbExp=5; IntAct=EBI-848624, EBI-1164361;
CC       P32322; P32322: PYCR1; NbExp=5; IntAct=EBI-848624, EBI-848624;
CC       P32322; O14787-2: TNPO2; NbExp=3; IntAct=EBI-848624, EBI-12076664;
CC   -!- SUBCELLULAR LOCATION: Mitochondrion {ECO:0000269|PubMed:19648921}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=P32322-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P32322-2; Sequence=VSP_044507;
CC       Name=3;
CC         IsoId=P32322-3; Sequence=VSP_054616;
CC   -!- DISEASE: Cutis laxa, autosomal recessive, 2B (ARCL2B) [MIM:612940]: A
CC       disorder characterized by an excessive congenital skin wrinkling, a
CC       large fontanelle with delayed closure, a typical facial appearance with
CC       downslanting palpebral fissures, a general connective tissue weakness,
CC       and varying degrees of growth and developmental delay and neurological
CC       abnormalities. Patients do not manifest metabolic abnormalities.
CC       {ECO:0000269|PubMed:19576563, ECO:0000269|PubMed:19648921}. Note=The
CC       disease is caused by variants affecting the gene represented in this
CC       entry.
CC   -!- DISEASE: Cutis laxa, autosomal recessive, 3B (ARCL3B) [MIM:614438]: A
CC       disorder characterized by an aged appearance with distinctive facial
CC       features, sparse hair, ophthalmologic abnormalities, intrauterine
CC       growth retardation, and cutis laxa. {ECO:0000269|PubMed:19648921,
CC       ECO:0000269|PubMed:22052856}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the pyrroline-5-carboxylate reductase family.
CC       {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAG17242.1; Type=Frameshift; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Mendelian genes pyrroline-5-carboxylate reductase 1
CC       (PYCR1); Note=Leiden Open Variation Database (LOVD);
CC       URL="https://databases.lovd.nl/shared/genes/PYCR1";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; M77836; AAA36407.1; -; mRNA.
DR   EMBL; AF218000; AAG17242.1; ALT_FRAME; mRNA.
DR   EMBL; AK297627; BAG60002.1; -; mRNA.
DR   EMBL; CR541769; CAG46568.1; -; mRNA.
DR   EMBL; AC145207; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471099; EAW89724.1; -; Genomic_DNA.
DR   EMBL; BC001504; AAH01504.1; -; mRNA.
DR   EMBL; BC071842; AAH71842.1; -; mRNA.
DR   CCDS; CCDS11794.1; -. [P32322-2]
DR   CCDS; CCDS11795.1; -. [P32322-1]
DR   CCDS; CCDS62366.1; -. [P32322-3]
DR   PIR; A41770; A41770.
DR   RefSeq; NP_001269209.1; NM_001282280.1. [P32322-1]
DR   RefSeq; NP_001269210.1; NM_001282281.1. [P32322-3]
DR   RefSeq; NP_008838.2; NM_006907.3. [P32322-1]
DR   RefSeq; NP_722546.1; NM_153824.2. [P32322-2]
DR   RefSeq; XP_005256438.1; XM_005256381.2. [P32322-1]
DR   RefSeq; XP_011521885.1; XM_011523583.2. [P32322-1]
DR   RefSeq; XP_011521886.1; XM_011523584.2. [P32322-1]
DR   PDB; 2GER; X-ray; 3.10 A; A/B/C/D/E=1-319.
DR   PDB; 2GR9; X-ray; 3.10 A; A/B/C/D/E=1-275.
DR   PDB; 2GRA; X-ray; 3.10 A; A/B/C/D/E=1-275.
DR   PDB; 2IZZ; X-ray; 1.95 A; A/B/C/D/E=1-300.
DR   PDB; 5UAT; X-ray; 1.92 A; A/B/C/D/E=1-300.
DR   PDB; 5UAU; X-ray; 1.90 A; A/B/C/D/E=1-300.
DR   PDB; 5UAV; X-ray; 1.85 A; A/B/C/D/E=1-300.
DR   PDB; 5UAW; X-ray; 1.85 A; A/B/C/D/E=1-300.
DR   PDB; 5UAX; X-ray; 1.85 A; A/B/C/D/E=1-270.
DR   PDB; 6XOZ; X-ray; 2.35 A; A/B/C/D/E=1-300.
DR   PDB; 6XP0; X-ray; 1.95 A; A/B/C/D/E=1-300.
DR   PDB; 6XP1; X-ray; 1.75 A; A/B/C/D/E=1-300.
DR   PDB; 6XP2; X-ray; 2.30 A; A/B/C/D/E=1-300.
DR   PDB; 6XP3; X-ray; 1.93 A; A/B/C/D/E=1-300.
DR   PDBsum; 2GER; -.
DR   PDBsum; 2GR9; -.
DR   PDBsum; 2GRA; -.
DR   PDBsum; 2IZZ; -.
DR   PDBsum; 5UAT; -.
DR   PDBsum; 5UAU; -.
DR   PDBsum; 5UAV; -.
DR   PDBsum; 5UAW; -.
DR   PDBsum; 5UAX; -.
DR   PDBsum; 6XOZ; -.
DR   PDBsum; 6XP0; -.
DR   PDBsum; 6XP1; -.
DR   PDBsum; 6XP2; -.
DR   PDBsum; 6XP3; -.
DR   SMR; P32322; -.
DR   BioGRID; 111789; 145.
DR   ComplexPortal; CPX-2085; Pyrroline-5-carboxylate reductase 1 complex.
DR   IntAct; P32322; 55.
DR   MINT; P32322; -.
DR   STRING; 9606.ENSP00000384949; -.
DR   ChEMBL; CHEMBL4296002; -.
DR   DrugBank; DB00157; NADH.
DR   DrugBank; DB00172; Proline.
DR   iPTMnet; P32322; -.
DR   MetOSite; P32322; -.
DR   PhosphoSitePlus; P32322; -.
DR   SwissPalm; P32322; -.
DR   BioMuta; PYCR1; -.
DR   DMDM; 60416434; -.
DR   EPD; P32322; -.
DR   jPOST; P32322; -.
DR   MassIVE; P32322; -.
DR   MaxQB; P32322; -.
DR   PaxDb; P32322; -.
DR   PeptideAtlas; P32322; -.
DR   PRIDE; P32322; -.
DR   ProteomicsDB; 1058; -.
DR   ProteomicsDB; 4639; -.
DR   ProteomicsDB; 54872; -. [P32322-1]
DR   TopDownProteomics; P32322-1; -. [P32322-1]
DR   Antibodypedia; 32938; 231 antibodies.
DR   DNASU; 5831; -.
DR   Ensembl; ENST00000329875; ENSP00000328858; ENSG00000183010. [P32322-1]
DR   Ensembl; ENST00000337943; ENSP00000336579; ENSG00000183010. [P32322-2]
DR   Ensembl; ENST00000402252; ENSP00000384949; ENSG00000183010. [P32322-3]
DR   Ensembl; ENST00000619204; ENSP00000479793; ENSG00000183010. [P32322-1]
DR   GeneID; 5831; -.
DR   KEGG; hsa:5831; -.
DR   UCSC; uc002kcp.5; human. [P32322-1]
DR   CTD; 5831; -.
DR   DisGeNET; 5831; -.
DR   GeneCards; PYCR1; -.
DR   HGNC; HGNC:9721; PYCR1.
DR   HPA; ENSG00000183010; Group enriched (pancreas, salivary gland, stomach).
DR   MalaCards; PYCR1; -.
DR   MIM; 179035; gene.
DR   MIM; 612940; phenotype.
DR   MIM; 614438; phenotype.
DR   neXtProt; NX_P32322; -.
DR   OpenTargets; ENSG00000183010; -.
DR   Orphanet; 357064; Autosomal recessive cutis laxa type 2B.
DR   Orphanet; 2078; Geroderma osteodysplastica.
DR   Orphanet; 293633; PYCR1-related De Barsy syndrome.
DR   PharmGKB; PA34064; -.
DR   VEuPathDB; HostDB:ENSG00000183010.16; -.
DR   eggNOG; KOG3124; Eukaryota.
DR   GeneTree; ENSGT00950000183044; -.
DR   InParanoid; P32322; -.
DR   OMA; VVRVMTN; -.
DR   OrthoDB; 952695at2759; -.
DR   PhylomeDB; P32322; -.
DR   BioCyc; MetaCyc:HS06848-MONOMER; -.
DR   BRENDA; 1.5.1.2; 2681.
DR   PathwayCommons; P32322; -.
DR   Reactome; R-HSA-8964539; Glutamate and glutamine metabolism.
DR   SABIO-RK; P32322; -.
DR   UniPathway; UPA00098; UER00361.
DR   BioGRID-ORCS; 5831; 16 hits in 995 CRISPR screens.
DR   ChiTaRS; PYCR1; human.
DR   EvolutionaryTrace; P32322; -.
DR   GeneWiki; PYCR1; -.
DR   GenomeRNAi; 5831; -.
DR   Pharos; P32322; Tbio.
DR   PRO; PR:P32322; -.
DR   Proteomes; UP000005640; Chromosome 17.
DR   RNAct; P32322; protein.
DR   Bgee; ENSG00000183010; Expressed in pancreas and 201 other tissues.
DR   ExpressionAtlas; P32322; baseline and differential.
DR   Genevisible; P32322; HS.
DR   GO; GO:0005759; C:mitochondrial matrix; TAS:Reactome.
DR   GO; GO:0005739; C:mitochondrion; IDA:UniProtKB.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0004735; F:pyrroline-5-carboxylate reductase activity; IDA:UniProtKB.
DR   GO; GO:0034599; P:cellular response to oxidative stress; IMP:UniProtKB.
DR   GO; GO:0009064; P:glutamine family amino acid metabolic process; TAS:Reactome.
DR   GO; GO:0055129; P:L-proline biosynthetic process; IBA:GO_Central.
DR   GO; GO:1903206; P:negative regulation of hydrogen peroxide-induced cell death; IMP:ParkinsonsUK-UCL.
DR   GO; GO:0006561; P:proline biosynthetic process; IDA:UniProtKB.
DR   GO; GO:0051881; P:regulation of mitochondrial membrane potential; IMP:ParkinsonsUK-UCL.
DR   HAMAP; MF_01925; P5C_reductase; 1.
DR   InterPro; IPR008927; 6-PGluconate_DH-like_C_sf.
DR   InterPro; IPR036291; NAD(P)-bd_dom_sf.
DR   InterPro; IPR028939; P5C_Rdtase_cat_N.
DR   InterPro; IPR029036; P5CR_dimer.
DR   InterPro; IPR000304; Pyrroline-COOH_reductase.
DR   Pfam; PF03807; F420_oxidored; 1.
DR   Pfam; PF14748; P5CR_dimer; 1.
DR   PIRSF; PIRSF000193; Pyrrol-5-carb_rd; 1.
DR   SUPFAM; SSF48179; SSF48179; 1.
DR   SUPFAM; SSF51735; SSF51735; 1.
DR   TIGRFAMs; TIGR00112; proC; 1.
DR   PROSITE; PS00521; P5CR; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; Amino-acid biosynthesis;
KW   Direct protein sequencing; Disease variant; Mitochondrion; NADP;
KW   Oxidoreductase; Phosphoprotein; Proline biosynthesis; Reference proteome;
KW   Stress response.
FT   INIT_MET        1
FT                   /note="Removed"
FT                   /evidence="ECO:0000269|Ref.8, ECO:0000269|Ref.9,
FT                   ECO:0007744|PubMed:19413330"
FT   CHAIN           2..319
FT                   /note="Pyrroline-5-carboxylate reductase 1, mitochondrial"
FT                   /id="PRO_0000187314"
FT   NP_BIND         6..11
FT                   /note="NADP"
FT                   /evidence="ECO:0000269|Ref.18"
FT   NP_BIND         69..72
FT                   /note="NADP"
FT                   /evidence="ECO:0000269|Ref.18"
FT   NP_BIND         95..97
FT                   /note="NADP"
FT                   /evidence="ECO:0000269|Ref.18"
FT   BINDING         34
FT                   /note="NADP; via carbonyl oxygen"
FT                   /evidence="ECO:0000269|Ref.18"
FT   BINDING         56
FT                   /note="NADP"
FT                   /evidence="ECO:0000269|Ref.18"
FT   MOD_RES         2
FT                   /note="N-acetylserine"
FT                   /evidence="ECO:0000269|Ref.8, ECO:0000269|Ref.9,
FT                   ECO:0007744|PubMed:19413330"
FT   MOD_RES         278
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         301
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   VAR_SEQ         1
FT                   /note="M -> MVGGGRRVGRDEPVPSVGALGQGSPDSM (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_054616"
FT   VAR_SEQ         290..319
FT                   /note="VKLDSPAGTALSPSGHTKLLPRSLAPAGKD -> DHLPLELGSPEGLHPLLL
FT                   QYQLARAPS (in isoform 2)"
FT                   /evidence="ECO:0000303|Ref.2"
FT                   /id="VSP_044507"
FT   VARIANT         119
FT                   /note="R -> G (in ARCL2B; dbSNP:rs121918376)"
FT                   /evidence="ECO:0000269|PubMed:19648921"
FT                   /id="VAR_059068"
FT   VARIANT         119
FT                   /note="R -> H (in ARCL2B; dbSNP:rs121918377)"
FT                   /evidence="ECO:0000269|PubMed:19648921"
FT                   /id="VAR_059069"
FT   VARIANT         179
FT                   /note="A -> T (in ARCL2B; dbSNP:rs139751598)"
FT                   /evidence="ECO:0000269|PubMed:19648921"
FT                   /id="VAR_059070"
FT   VARIANT         189
FT                   /note="A -> V"
FT                   /evidence="ECO:0000269|PubMed:19648921"
FT                   /id="VAR_059071"
FT   VARIANT         206
FT                   /note="G -> R (in ARCL2B; dbSNP:rs121918375)"
FT                   /evidence="ECO:0000269|PubMed:19648921"
FT                   /id="VAR_059072"
FT   VARIANT         206
FT                   /note="G -> W (in ARCL2B; dbSNP:rs121918375)"
FT                   /evidence="ECO:0000269|PubMed:19648921"
FT                   /id="VAR_059073"
FT   VARIANT         248
FT                   /note="G -> E (in ARCL3B; results in a reduction of protein
FT                   expression in skin fibroblasts from the patient;
FT                   dbSNP:rs281875319)"
FT                   /evidence="ECO:0000269|PubMed:22052856"
FT                   /id="VAR_067600"
FT   VARIANT         251
FT                   /note="R -> H (in ARCL3B; dbSNP:rs121918378)"
FT                   /evidence="ECO:0000269|PubMed:19648921"
FT                   /id="VAR_059074"
FT   VARIANT         257
FT                   /note="A -> T (in ARCL3B; dbSNP:rs281875318)"
FT                   /evidence="ECO:0000269|PubMed:19648921"
FT                   /id="VAR_059075"
FT   VARIANT         266
FT                   /note="R -> Q (in ARCL2B; may cause skipping of exon 6;
FT                   dbSNP:rs121918374)"
FT                   /evidence="ECO:0000269|PubMed:19576563"
FT                   /id="VAR_059076"
FT   VARIANT         297
FT                   /note="G -> R"
FT                   /evidence="ECO:0000269|PubMed:22052856"
FT                   /id="VAR_067601"
FT   MUTAGEN         221
FT                   /note="E->A: Reduced enzyme activity."
FT                   /evidence="ECO:0000269|PubMed:16730026"
FT   CONFLICT        155
FT                   /note="S -> T (in Ref. 1; AAA36407)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        317
FT                   /note="G -> S (in Ref. 4; CAG46568)"
FT                   /evidence="ECO:0000305"
FT   STRAND          3..7
FT                   /evidence="ECO:0007744|PDB:5UAV"
FT   HELIX           10..21
FT                   /evidence="ECO:0007744|PDB:5UAV"
FT   HELIX           27..29
FT                   /evidence="ECO:0007744|PDB:5UAV"
FT   STRAND          30..33
FT                   /evidence="ECO:0007744|PDB:5UAV"
FT   HELIX           40..48
FT                   /evidence="ECO:0007744|PDB:5UAV"
FT   STRAND          51..54
FT                   /evidence="ECO:0007744|PDB:5UAV"
FT   HELIX           56..62
FT                   /evidence="ECO:0007744|PDB:5UAV"
FT   STRAND          64..68
FT                   /evidence="ECO:0007744|PDB:5UAV"
FT   HELIX           72..74
FT                   /evidence="ECO:0007744|PDB:5UAV"
FT   HELIX           75..82
FT                   /evidence="ECO:0007744|PDB:5UAV"
FT   HELIX           83..85
FT                   /evidence="ECO:0007744|PDB:5UAV"
FT   STRAND          91..94
FT                   /evidence="ECO:0007744|PDB:5UAV"
FT   HELIX           101..109
FT                   /evidence="ECO:0007744|PDB:5UAV"
FT   STRAND          112..114
FT                   /evidence="ECO:0007744|PDB:5UAW"
FT   STRAND          116..121
FT                   /evidence="ECO:0007744|PDB:5UAV"
FT   HELIX           124..128
FT                   /evidence="ECO:0007744|PDB:5UAV"
FT   STRAND          131..137
FT                   /evidence="ECO:0007744|PDB:5UAV"
FT   HELIX           143..154
FT                   /evidence="ECO:0007744|PDB:5UAV"
FT   STRAND          157..161
FT                   /evidence="ECO:0007744|PDB:5UAV"
FT   HELIX           164..166
FT                   /evidence="ECO:0007744|PDB:5UAV"
FT   HELIX           167..173
FT                   /evidence="ECO:0007744|PDB:5UAV"
FT   TURN            174..176
FT                   /evidence="ECO:0007744|PDB:5UAV"
FT   HELIX           177..194
FT                   /evidence="ECO:0007744|PDB:5UAV"
FT   HELIX           199..218
FT                   /evidence="ECO:0007744|PDB:5UAV"
FT   HELIX           224..230
FT                   /evidence="ECO:0007744|PDB:5UAV"
FT   HELIX           237..247
FT                   /evidence="ECO:0007744|PDB:5UAV"
FT   HELIX           250..273
FT                   /evidence="ECO:0007744|PDB:5UAV"
SQ   SEQUENCE   319 AA;  33361 MW;  9E8C4DED0638EFC5 CRC64;
     MSVGFIGAGQ LAFALAKGFT AAGVLAAHKI MASSPDMDLA TVSALRKMGV KLTPHNKETV
     QHSDVLFLAV KPHIIPFILD EIGADIEDRH IVVSCAAGVT ISSIEKKLSA FRPAPRVIRC
     MTNTPVVVRE GATVYATGTH AQVEDGRLME QLLSSVGFCT EVEEDLIDAV TGLSGSGPAY
     AFTALDALAD GGVKMGLPRR LAVRLGAQAL LGAAKMLLHS EQHPGQLKDN VSSPGGATIH
     ALHVLESGGF RSLLINAVEA SCIRTRELQS MADQEQVSPA AIKKTILDKV KLDSPAGTAL
     SPSGHTKLLP RSLAPAGKD
//
